<DOC>
	<DOCNO>NCT01456845</DOCNO>
	<brief_summary>The purpose study estimate plasma drug level ( free total drug level ) rifampicin antituberculosis drug compare drug level patient develop drug induce hepatotoxicity versus .The study hypothesis ATT drug induce hepatotoxicity relate free drug level rifampicin antituberculosis drug .</brief_summary>
	<brief_title>Anti-tuberculosis ( TB ) Drug Levels Correlation With Drug Induced Hepatotoxicity</brief_title>
	<detailed_description>Tuberculosis ( TB ) major health problem develop developed country resurgence immunosuppressed patient . World Health Organization ( WHO ) 1993 declare tuberculosis 'global emergency ' third world 's population infect . Globally 8.9 million new case tuberculosis occur annually , 1.8 million ( 20 % ) occur India . Short-course chemotherapy contain isoniazid ( INH ) , rifampicin ( RMP ) pyrazinamide ( PZA ) prove highly effective treatment tuberculosis . One adverse effect hepatotoxicity . It common side effect lead interruption therapy . It associate mortality 6-12 % drug continue even onset symptom . Risk hepatotoxicity increase drug combine . The time interval start anti-TB drug appearance hepatotoxicity vary 3 135 day . In case hepatitis evident within three month start antituberculosis treatment ( ATT ) . The pathogenesis drug-induced hepatotoxicity ( DIH ) still entirely clear anti TB drug include rifampicin . Hypersensitivity definite possibility . Rifampicin induce hepatitis postulate occur part systemic allergic reaction due unconjugated hyperbilirubinaemia result competition bilirubin uptake hepatocyte plasma membrane . DIH cause rifampicin occur early compare isoniazid . While dose related toxicity may exist , direct correlation serum drug level hepatotoxicity well report . Thus clinical relevance therapeutic monitoring serum rifampicin concentration manage DIH still explore . Rifampicin highly protein bound hypoalbuminemia know risk factor DIH , free drug level plasma significance total drug level plasma . Present study do estimate free total drug level rifampicin antituberculosis drug patient ATT compare patient develop DIH v ass predict ability drug level subsequent development drug induce hepatoxicity .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Drug-Induced Liver Injury</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<criteria>Age : patient range 18 65 year Patients either gender Probable confirmed case TB Patients receive daily antituberculosis drug Patients serological evidence acute viral hepatitis A , B , C , E carrier HBV and/or HCV HIV positive patient Presence chronic liver disease cirrhosis Cognitive dysfunction Terminally sick patient unlikely survive 69 month Concomitant administration potentially hepatotoxic drug ( Methotrexate , Phenytoin , phenobarbitone , carbamazepine , valproate Atenolol , labetalol , Salicylates , allopurinol , quinine , quinidine , fluconazole , cimetidine , ethionamide , verapamil , probenecid , TCA , halothane ) Chronic alcoholic consume &gt; 48 g/day 1 year Patients willing give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Plasma level</keyword>
	<keyword>isoniazid</keyword>
	<keyword>rifampicin</keyword>
	<keyword>pyrazinamide</keyword>
	<keyword>hepatoxicity</keyword>
</DOC>